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As David B. Nash, M.D., M.B.A., takes the helm of Disease Management as Editor-in-Chief, the
practice of disease management—now a decade old—depends on its practitioners to continue to provide
“economic proof of concept.” This effort to accrue the credibility needed to design and fund programs will
provide further evidence that new technologies can be integrated into care programs across large popula-
tions to reduce costs while improving healthcare and access to it.
Q: Why is this a particularly opportune time
for you to become Editor-in-Chief of Disease
Management?
A: First, we’re thrilled to have this new re-
sponsibility and recognition of our work in the
field. So we’re very grateful to Mary Ann
Liebert, Inc., for thinking of us in this role. And,
secondarily, we believe disease management is
at a critical crossroads at the beginning of this
new century. This idea has been around for al-
most a decade, and one of the many challenges
that disease management still faces is “eco-
nomic proof of concept.” In other words, have
we really been able to demonstrate that all of
the great tools that we’ve created over the last
decade—interactive voice recognition technol-
ogy and related tools—have we been able to
demonstrate that these tools really are going to
improve clinical outcomes and reduce costs at
the same time?
Dr. Nash and the members of the Editorial Board of Disease Management welcome comments and questions from
readers. Please direct queries and comments to Dr. Nash at the Office of Health Policy & Clinical Outcomes, Jeffer-
son Medical College, 1015 Walnut Street, Suite 115, Philadelphia, PA 19107. Telephone: (215) 955-6969; fax: (215) 923-
7583; e-mail: David.Nash@mail.tju.edu
I think at the moment there is modest proof
of the concept. We thought by taking over the
only peer-reviewed journal in the field that we
would accrue the research evidence to support
the idea that disease management indeed
works.
So I think it is a great opportunity for us to
jump right into the fray at a crucial time, really
the crossroads, for disease management.
Q: The term itself, “disease management,”
as you noted, for the past decade has been
making inroads from mainly managed care
entities. Do you sense in the past two or three
years that it is making inroads beyond the
original set of “true believers” who imple-
ment programs?
A: Yes. I think that disease management has
evolved, especially over the past four to five
years. Here’s how. Originally, disease man-
agement seemed to be exclusively a patient ed-
ucation program fostered and promoted by the
pharmaceutical industry. The industry worked
very hard, of course, to promote their own
products. Providers, both doctors and man-
aged care organizations, recognized over time,
as did the pharmaceutical industry, that this
sole method was not going to work.
In addition, the growth of the Internet and
other technologies—the confluence of these
events: the pharmaceutical companies realizing
that individual drug programs [were not going
to be successful] and the growth of the Inter-
net—together dramatically altered the face of
disease management just within the last three
to four years. Specifically, I think the pharma-
ceutical industry recognized that sophisticated
brochures that were product-specific were not
going to have an impact on patients’ behavior.
The pharma industry realized that the day-to-
day work of getting patients to comply with
any kind of clinical program is messy, and it is
complicated. I have written on this subject
about the pharmaceutical industry not really
appreciating the power of “the white coat” and
the complexity of the doctor-patient relation-
ship. It is not their area of concern, historically
speaking. When they began to appreciate just
how complicated compliance programs were,
they began to retreat from disease manage-
ment, per se.
At around that same time, we had the growth
of consumerism and the Internet, interactive
voice recognition, e-mail, and it became clear
that these new technologies could completely
transform the disease management field. And
I think, again, it goes back to our first question,
that is, why I believe we’re at the crossroads.
The pharmaceutical industry has taken a back
seat, new technologies have come, and we have
an opportunity to prove the concept in every-
day practice.
Q: Let’s pick up for a moment on your men-
tion of the Internet and the Age of Con-
sumerism, using the example of the Winona
Health Online Group. The outcomes of that
study show, perhaps for the first time, that
consumers are comfortable with the Internet
being involved in a most personal aspect of
their lives—their health data gathered from
their living rooms. What does this step mean
in terms of helping provide proof of out-
comes?
A: As you know, the Cerner Corporation in
Kansas City—along with an outside advisory
board and people from the University of Min-
nesota Medical School and School of Public
Health and Cap Gemini–Ernst and Young—
support what I would call a large social exper-
iment in a small town of 26,000 outside Min-
neapolis called Winona. The idea here is to take
the town and essentially create a randomized
trial, or at least an observational trial, based on
giving half of the town access to these new tech-
nologies, while the other half will lack access
to them. The goal at the end of two years is to
measure the impact of the technologies on
health outcomes, on access to care, on patient
satisfaction, and on utilization of resources.
I think it is premature to say we have had an
impact. We have just started the program.
Winona has one hospital and about 100 doc-
tors. So it is a town where this kind of experi-
ment is possible. It is relatively isolated from
other towns, so it is a kind of natural experi-
mental place. But I give a lot of credit to the
leadership of Cerner. I give a lot of credit to
Cap Gemini–Ernst & Young for their support
early on, and a lot of credit to the faculty at the
University of Minnesota who have been very
supportive in creating the advisory board for
this social experiment.
I think the results are going to be very im-
portant. I do not want to say that they will
make or break the situation, but clearly the re-
sults of the Winona experiment will give us
some sense of impact of these programs and
perhaps even a guidepost for the future.
Winona will give us a sense of what works and
what doesn’t. Because the field is so young and
there are no experiments comparable to
Winona, results will be critically important.
Q: Let’s talk about the concept of outcomes
that are needed. Do you feel through your
work in the field that the outcomes proof is
needed more for the providers or the payers,
or is it pretty much an even split?
A: My own belief is that the need for good
outcomes information is shared by all stake-
holders. Providers will not practice disease
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management unless they see it has a patient-
specific outcome. Payers will not pay for dis-
ease management unless they see a population-
based outcome. I don’t think patients will
participate in disease management unless they
see an improvement in their own condition.
Our own research, specifically on diabetes dis-
ease-management programs, which has been
published in Diabetes Care, points out that pa-
tients have very definite feelings—positive and
negative—that one can measure in a repro-
ducible, valid way, about the quality of the dis-
ease management program itself. And we
found evidence of that in our work with a di-
abetes disease-management evaluation tool
which we call the DMET. Others have done
work in this field as well. We are trying to eval-
uate the impact on the patient. So to get back
to your question, every stakeholder in the sys-
tem is interested in the outcomes, and that’s
one of the main reasons we wanted to get in-
volved with Disease Management, to serve as the
principal vehicle to promote an agenda about
outcomes measurement. For the past twelve
years, our Office of Health Policy and Out-
comes here at Jefferson Medical College has
been devoted to these issues.
Q: In terms of patients seeking care, not
limiting the discussion to demographics or a
particular generation of patients, compared to
say twenty years ago, is there a difference in
acceptance of preventive care?
A: Research evidence supports the fact that
the tail end of the Baby Boom generation—
those born between 1955 and 1965, those en-
tering AARP [American Association of Retired
Persons] age—are very concerned with pre-
ventive measures. They want to prevent aging.
They want to prevent cancer. They want to pre-
vent osteoporosis. I think younger genera-
tions—Generation X, Generation Y—still be-
lieve in their immortality to some extent. But I
think in general terms, the entire population is
much more in tune with issues like lipid-low-
ering therapy, erectile dysfunction, staying in
good physical condition, due in no small part
to direct-to-consumer advertising and the
power of consumerism in general. But, specif-
ically that Baby Boomers are one of our key au-
diences for disease management. They also
have aging parents who suffer all of the chronic
illnesses for which many disease management
programs have been designed. So there are key
sectors within the population who are inter-
ested in these programs.
Q: You have assembled quite an outstand-
ing Editorial Board. Will you comment on
your expectations of the members?
A: We’re very proud of the sixty or so per-
sons from around the country who have agreed
to serve. Let me tell you a little about the Board.
We went to every sector in healthcare to reach
out to national thought leaders, practitioners,
public and private sector individuals, acade-
mics, provider groups—virtually every sector
is represented by members of the Editorial
Board. We asked Editorial Board members to
pledge to us that they would help us recruit ar-
ticles, reviews, and write on topics themselves.
We have nationally prominent persons from
each possible division within the healthcare
sector. I’m also excited because we have per-
sons from the pharmaceutical industry, people
from the disease management industry itself.
These are people who have been in the
trenches, who are practitioners of disease man-
agement and have the scars to prove it. We
have academicians who are experts in out-
comes measurement. We have people from
managed care who support and pay for disease
management programs. We have people from
consumer groups who are the beneficiaries (or
the victims) of disease management programs.
We strove for the broadest possible represen-
tation, and we assigned them real work to do.
We hope they are as proud of their service as
we are to have them.
Q: Is there more original research being de-
signed and carried out to prove healthcare
outcomes, or is there still resistance from
funding sources to attempt to prove that pre-
ventive care provides benefits over the long
term?
A: Regrettably, I think there is resistance
from funding sources at this moment in time.
We hope that through the Journal and good re-
search that we will erode some of that resis-
tance. That is a very important question about
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the marketplace. I’m also hoping that the jour-
nal will be a lightning rod to spur other peo-
ple on to doing research. Our motto is, “In God
we trust; all others bring data.” We want to pro-
mulgate that way of thinking. We want to dis-
seminate good projects in the hopes of stimu-
lating others to question and evaluate their
own programs. How do we know where we’re
going if we don’t measure where we are cur-
rently? I think disease management has really
suffered, especially in the last three years, from
a lack of measurement and a lack of self-eval-
uation, and we see the Journal as a lightning
rod for both of those areas.
Q: If we could ask you to put on your fu-
turist’s cap for a moment, reflecting on the
work that has been done in the past ten years,
as well as ongoing work, would you tell us
what you think is in store for the healthcare
profession and patient care within disease
management programs in the next ten or
twenty years?
A: As Will Rogers said, “There is no future in
predicting the future.” But here goes. I think the
widespread application of the Internet, e-mail,
and related tools will eventually lead us to what
Wall Street calls “the mass customization of clin-
ical information,” which means our ability to
share, through e-mail and other technologies,
specific patient-related lab tests, educational ma-
terial, and feedback from providers. I envision a
wireless, Web-based world of people receiving
on a continuous, longitudinal basis, information
about their healthcare through disease manage-
ment companies and technologies in concert
with their providers. People will be in constant
communication, whenever they feel like it, with
their providers—getting new educational mate-
rial, reporting their blood sugar levels if they
have diabetes, their weight if they have heart fail-
ure, their forced expiratory volume if they have
asthma. Whatever it is, I think we will be able to
customize our approach to disease management,
harnessing the power of the Internet. There are,
as you know, many companies attempting to do
this now. We are involved in some of them.
Many of them are represented on the Editorial
Board, like Doctor Quality, Medscape, and oth-
ers. I’m very excited about the whole industry
that I see coming in the next decade of wireless,
Web-based, completely transportable, clinical
feedback of information. It is a very exciting
prospect for the future.
—Interview conducted by Tim Basting
Associate Editor
Disease Management
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